Podcasts about IQVIA

AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset's chance for success. On a special edition of the BioCentury This Week podcast, IQVIA's Greg Lever joins BioCentury's analysts to discuss agentic AI's short- and long-term prospects to help biotechs discover new targets, predict success in preclinical development, and enhance clinical operations. This episode of BioCentury This Week is sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/657086#Biotech #Biopharma #DrugDevelopment #ClinicalTrials #TargetDiscovery #AgenticAI #GraphRAG #DeRisking00:01 - Sponsor Message: IQVIA Biotech01:22 - AI in Biotech05:01 - Machine Learning06:21 - Generative AI and Language Models08:37 - Agentic AI12:43 - AI in Target Discovery23:44 - AI in Clinical Trial DesignTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this episode presented by IQVIA, BioSpace's head of insights Lori Ellis discusses the importance of target product profiles, particularly when navigating funding challenges, with Ian Fisher, head of development analytics.

In this episode, BioSpace's head of insights Lori Ellis discusses the FDA's first draft guidance for AI in drug development, published in January 2025, with Archana Hegde, Senior Director, PV systems and innovations at IQVIA.

Send us a textDrug-resistant germs are hidden killers in more than one way. Not only are the microbes invisible to the human eye, in many places, they're invisible because people simply are not looking for them systematically.Doctors often do not know what infections their patients have and treat them based on best guesses, which allows for ineffective treatments and exacerbates drug resistance. Policymakers don't know which infections are most common among populations and cannot make informed decisions about needed treatments or vaccines.This is a major problem across Africa and a new report shows just how complex the problem is.The Mapping AMR and Antimicrobial use Partnership (MAAP), which included the One Health Trust as well as the African Society for Laboratory Medicine; Africa CDC; the East, Central, and Southern Africa Health Community; Innovative Support to Emergencies, Diseases, and Disasters, a nonprofit focused on technology and communication;  the clinical research group IQVIA; and the West African Health Organization, collected data from laboratories from 14 countries in Africa (Burkina Faso, Cameroon, Gabon, Ghana, Kenya, Eswatini, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe). “The study revealed significant gaps in bacteriology testing capacities,” the group, whose work was paid for by the UK government's Fleming Fund, wrote in PLoS Medicine.It's the biggest survey yet of testing for antimicrobial resistance – AMR or drug resistance – in Africa.Among the gaps: too little testing overall, a lack of laboratory capacities, and poor coordination and analysis of records. Many records were kept only on paper, which made them almost impossible to access.None of this surprises Dr. Sabiha Essack, South African Research Chair in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal. In an ideal world, she says, a doctor, nurse or other professional should see a patient, test them to see what specific microbe is causing an infection, check to see which drugs will successfully fight that germ, and then treat the patient accordingly.Cheap point-of-care tests should be available everywhere and the results of those tests should be entered into systems that officials can use to make policy decisions, she says. Listen as she tells One World, One Health host Maggie Fox other ways to improve our knowledge about the drug-resistant infections that lurk out there. Want to know more? You can find One World, One Health episodes on drug-resistant infections in cancer patients; superbugs and microplastics; the personal toll of antibiotic resistance; one woman's antibiotic resistance nightmare; how to prevent drug resistance, and more.

In this episode, BioSpace's head of insights Lori Ellis discusses the evolving role of local qualified persons for pharmacovigilance with ⁠Ana Pedro Jesuíno⁠, global head local QPPV network at IQVIA.

Clinical trials are growing more complex, and nowhere is that more evident than in oncology and obesity research. As sponsors push for reliable, real-time patient data, the role of electronic clinical outcome assessments (eCOAs) has never been more critical. These tools determine not only how patients report on their quality of life but also how sponsors capture the endpoints that drive regulatory approval. In this episode of the AI in Business podcast, Emerj Editorial Director Matthew DeMello speaks with Anthony Mikulaschek, Vice President of Commercial Strategy at IQVIA Technologies. Anthony unpacks the evolution of eCOAs, from their early days on Palm Pilots to today's AI-enabled platforms. He explains how thoughtful design reduces patient and clinician burden, why cultural and linguistic nuance matters for global trials, and what digital libraries and compliance automation mean for faster, more resilient studies. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Eli Lilly posted data Tuesday from a second Phase III trial of its oral weight loss therapy orforglipron, providing the company with all it needs to head to the FDA with a new drug application. For more in-depth discussion on the oral weight-loss space, check out a special episode of The Weekly. And stay tuned to BioSpace for more unique coverage of this market as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland. On the business side of biopharma, AbbVie turned back to neuropsychiatric therapies this week, acquiring partner Gilgamesh Pharmaceuticals' lead depression candidate for $1.2 billion. The deal is a display of resilience for AbbVie in the neuropsychiatric space as well, after the stunning failure last November of schizophrenia asset emraclidine—picked up in its nearly $9 billion acquisition of Cerevel Therapeutics. And is the cooler late summer weather thawing the IPO market? Neuropsych-focused LB Pharma revealed in an SEC filing on Friday that it plans to take the plunge, ending a six-month stalemate in biotech IPOs.  Finally, the Department of Health and Human Services (HHS) has been busy this past week. On Monday, the CDC named Retsef Levi—a known vaccine critic—to head the agency's COVID-19 immunization working group, just as reports surfaced that the Trump administration could be “within months” of banning the COVID-19 vaccine in the U.S. Meanwhile, the FDA issued new draft guidance for cancer drug developers that prioritizes the use of survival data, and the agency began publishing drug-related adverse event reports daily.   HHS itself has also been the subject of recent headlines, announcing that it will no longer recognize employee unions, and last week, hundreds of HHS staffers penned an open letter calling on Secretary Kennedy to tone down what they called “dangerous and deceitful statements” that have fostered distrust against federal health workers, exposing them to physical harm. This followed the Aug. 8 shooting at CDC headquarters in Atlanta.   Finally, multinational pharmaceutical companies spent more than $48 billion on partnerships with China in the first half of 2025 alone, according to a new report from IQVIA—more than in all of 2024.  

In this episode of the Astonishing Healthcare podcast, Mike Miele, FSA, MAAA (SVP of Insured Services), joins us again for a lively discussion about a new product and the growth of level-funded pharmacy plans. What are level-funded plans? How does Capital Rx's "Capital Equilibrium" work? Listen in to hear how these plans, positioned between self-funded and fully insured models, offer employers budget certainty while maintaining flexibility and transparency. Mike highlights the scenarios where a level-funded plan can truly help - e.g., a municipality with a fixed budget and the role stop-loss plays (building on Episode 55), and he also notes that not all level-funded plans are equal, and plan sponsors should look for transparency around rebates and whether any savings - if a plan's performance is better than the guarantee - ultimately benefit the plan.Related ContentAH071 - A Look at What's Really Driving Drug Spend, and How it Impacts Us, with IQVIA's Michael KleinrockPharmacy Benefits 101: Pharmaceutical RebatesAH067 - Aligned Health Benefits and the Freedom to Unbundle, with Kristin Begley, PharmDHow to Manage Pharmacy Benefit Spend in a GLP-1 WorldFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

This episode focuses on how Agentic AI is shaping the future of clinical research. In this episode you will:  Learn about the differences between an AI agent and an agentic framework and how the latter can coordinate and orchestrate many different AI agents to answer more complex questions.  Explore the capabilities of Agentic AI and its applications in clinical trials and early clinical development. Hear how an Agentic AI framework provided a pharma company with a roadmap a decade out to see how to optimally develop their R&D pipeline for a therapeutic area of interest.  Greg Lever, Director of AI Solutions Delivery at IQVIA, is our featured guest.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: FDA approves the first fast-acting biosimilar insulin in the US, Tandem issues warning, DOJ stands up for remote monitoring in schools, GLP1 use protects against dementia, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX We've got the first and only biosimilar FDA approved and moving to market. Kirsty – insulin aspart, which is a biosimilar to Novolog will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use. KIRSTY has been available in Europe and Canada since 2022. This same company makes Semglee, the first biosimilar for long acting? Sales of Insulin Aspart in the United States were approximately $1.9 billion in 2024, according to IQVIA. https://www.globenewswire.com/news-release/2025/07/15/3115973/0/en/Biocon-Biologics-Expands-Diabetes-Portfolio-with-FDA-Approval-of-Kirsty-the-First-and-Only-Interchangeable-Rapid-Acting-Insulin-Aspart-in-the-United-States.html XX Tandem Diabetes Care (Nasdaq:TNDM) has issued an urgent medical device correction for some t:slim X2 automated insulin pumps. In a July 22 notice, the San Diego-based company warned of pumps that may exhibit a higher rate of speaker failure. During normal use, the insulin pump software monitors current flowing through the speaker during use. Measurements that fall within a pre-determined range indicate a functioning speaker. Meanwhile, measurements falling outside the range indicate a speaker failure.   When the measurements land outside the expected range, the system declares a malfunction, referred to as “Malfunction 16.” If the pump declares this malfunction, insulin delivery will stop and the pump will no longer be operational. Malfunction 16 terminates communication between the pump and continuous glucose monitor (CGM), as well as the t:slim mobile app.   If not addressed, the issue can lead to hyperglycemia, which can result in hospitalization or medical intervention. The company reports 700 adverse events and 59 reported injuries to date, with no reports of death.   Tandem identified that certain speaker versions have a higher rate of Malfunction 16 events due to a wiring issue within the speaker. Users can continue using their pump but with added precautions because Malfunction 16 can occur at any time. They should use the t:slim mobile app with push notifications turned on so the app alerts them if the malfunction occurs, the company said.   Additionally, Tandem intends to release a software update aimed at enhancing the early detection of speaker failure. The update also introduces persistent vibration alarms to help reduce potential safety risk. Tandem plans to notify affected pump users when it makes the update available. https://www.drugdeliverybusiness.com/tandem-warns-insulin-pump-speaker-malfunction/ XX BIG WIN! The DOJ protects T1D rights again! The US Attorney's office for the Western District of Washington State reached a settlement with a public school district that once again confirms remotely monitoring students' CGMs is a reasonable accommodation that schools must provide to comply with the Americans with Disabilities Act. If its true for one state its true for all states under federal law! If your local schools still refuse to remotely monitor CGMs of their students, provide them with this letter to compel them to FOLLOWT1Ds and FOLLOW Federal Laws. If they still refuse contact us! https://followt1ds.org/ XX new study finds people taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin users. Past studies show that people who have type 2 diabetes — a chronic condition where the body does not use its insulin properly — are at a higher risk of developing dementia. The study found that when comparing the neuroprotective abilities of two diabetes medications — metformin and glucagon-like peptide-1 receptor agonists (GLP-1 agonists) — participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin.   https://www.medicalnewstoday.com/articles/glp-1s-may-offer-better-dementia-protection-than-metformin XX Front office changes coming to Dexcom.  CEO Kevin Sayer will step down  & give the reins to current Chief Operating Officer Jake Leach. Scheduled for January 1, 2026, Leach will also join Dexcom's board of directors where Sayer will remain  executive chairman. One of our frequent guests here.. Leach has worked at Dexcom for 21 years. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. https://www.medtechdive.com/news/dexcom-ceo-change-kevin-sayer-jake-leach/756382/ XX A major international study has revealed that many children and young adults in Sub-Saharan Africa who are diagnosed with type 1 diabetes (T1D) may actually have a different, non-immune-based form of the condition. Unlike the traditional autoimmune version of T1D, this form appears to develop without the immune system attacking the insulin-producing cells. This finding could significantly reshape how diabetes is diagnosed and treated across the region, potentially leading to more precise care and better health outcomes. The researchers found that many young people in Sub-Saharan Africa diagnosed with T1D often don't have the usual markers in their blood (called islet autoantibodies) typically seen in people with T1D in other parts of the world. Specifically, 65% of participants with T1D in this region did not have islet autoantibodies. When the researchers compared this data to studies in the U.S., they found a smaller but significant proportion (15%) of Black participants diagnosed with T1D had a similar form of diabetes found in Sub-Saharan Africa – characterized by negative autoantibodies and a low T1D genetic risk score.   However, white Americans with T1D showed the typical autoimmune pattern, even if they didn't have detectable autoantibodies, their genetics still pointed to autoimmune diabetes.   “The identification of this T1D diabetes subtype in Sub-Saharan African populations and among individuals of African ancestry in the U.S. suggests a potential ancestral or genetic link,” Dabelea notes. “These findings highlight the need to consider alternative etiologies in this group and a deeper understanding of the underlying mechanisms may provide important insights for future prevention and treatment strategies.”     https://scitechdaily.com/new-diabetes-subtype-discovered-in-africa-challenges-global-assumptions/   XX Formal recognition for the specialty of Diabetology.   Diabetology is the specialty focused on the full continuum of diabetes care — encompassing diagnosis, treatment, prevention, technology integration, education, and cardiometabolic management. While it intersects with endocrinology, primary care, and public health, diabetology is uniquely defined by its depth and focus on diabetes alone.       The American College of Diabetology (ACD) is the national professional organization representing clinicians who specialize in diabetes care. ACD advances clinical excellence and education to improve the lives of those affected by diabetes. https://www.businesswire.com/news/home/20250725766248/en/American-College-of-Diabetology-Announces-Formal-Taxonomy-Classification-for-Diabetology   XX Tidepool announces cloud-to-cloud integration with Abbott's FreeStyle Libre portfolio. From the release: This integration allows people living with diabetes using the FreeStyle Libre portfolio to connect their data to their Tidepool account seamlessly. For healthcare providers, this means more comprehensive insights and streamlined workflows, with FreeStyle Libre systems data flowing continuously into the Tidepool Data Platform. https://www.tidepool.org/blog/abbott-freestyle-libre-integration-launched XX Stelo dexom ai food XX With high drug prices remaining an ongoing concern for U.S. politicians, Roche is considering following in the footsteps of some of its peers with a direct-to-consumer (DTC) model to cut out the middlemen.     About 50% of the money spent on drugs in the U.S. healthcare system goes straight to PBMs instead of the companies that create the medicines, Roche CEO Thomas Schinecker called out in a press conference on Thursday.   Bringing the drugs directly to the consumer could be a solution to positively impact pricing for patients “without destroying innovation,” Schinecker added on a separate Thursday call with investors, noting that the company has discussed the matter with the U.S. government and its Department of Health and Human Services. The pricing talks come after President Donald Trump inked a “Most Favored Nation” executive order in May, aiming to tie U.S. drug prices to lower prices in other developed nations. The plan was quickly called out by industry voices such as the PhRMA trade group, which labeled it a “bad deal” for U.S. patients. https://www.fiercepharma.com/pharma/roche-weighing-direct-consumer-drug-sales-ease-us-drug-pricing-woes-cut-out-pbms-ceo-says XX SAB BIO secures substantial $175M financing to advance T1D therapy with impressive investor lineup and extended cash runway until 2028. Most critically, this financing fully funds the pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune Type 1 diabetes in newly diagnosed patients. By extending the cash runway into mid-2028, SAB has effectively eliminated near-term financing risk and provided clear visibility through this crucial clinical trial and potential commercialization preparation. Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners         https://www.stocktitan.net/news/SABS/sab-bio-announces-oversubscribed-175-million-private-fwsf2t91ek4z.html   XX In a landmark 14-year study, researchers have found that artificially sweetened drinks raise the risk of developing type 2 diabetes by more than a third, significantly higher than those loaded with sugar. It challenges the long-standing perception of diet drinks being a healthier alternative and suggests they may carry metabolic risks of their own. In the first longitudinal study of its kind, led by Monash University, researchers tracked 36,608 participants over an average period of 13.9 years to assess how both sugar-sweetened beverages (SSBs) and artificially sweetened beverages (ASBs) impacted health outcomes. The self-reported health data, from the Melbourne Collaborative Cohort Study, was drawn from participants aged 40 to 69 years at the time of recruitment.   What they found was that drinking just one can of artificially sweetened soda increased the risk of developing type 2 diabetes by 38%, compared to people who didn't consume these drinks at all. For those consuming the same amount of sugary drinks, the risk was 23% higher. This suggests there's more than obesity at play. The researchers believe this result is due to an independent metabolic effect, possibly gut microbiome disruption or a change in glucose metabolism.   While the study didn't identify which artificial sweeteners were at play,   Evidence suggests that artificial sweeteners can alter the composition and function of gut bacteria, leading to glucose intolerance – a precursor to type 2 diabetes. And that some sweeteners may trigger insulin release, desensitize metabolic responses over time, or confuse the body's glucose regulation system – even without actual sugar in the picture.   Another hypothesis is that regular exposure to the kind of intense sweetness that artificial products deliver may condition the body to anticipate sugar calories that never come, affecting appetite regulation, insulin sensitivity and broader metabolic pathways. However, the authors suggest that how sweeteners affect the gut microbiota and glucose regulation are the most likely drivers of increased diabetes risk.   https://newatlas.com/diet-nutrition/one-drink-diabetes-risk/ XX After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an affordability challenge to the state and Marylanders.   The state Prescription Drug Affordability Board approved two resolutions saying that prescription drugs Jardiance and Farxiga likely pose an “an affordability challenge for the state health care system” and the state should look for ways to bring down those costs.   Health care advocates call the long-awaited resolution an “important first step” in the process in bringing down prescription costs for those on the state's health plan.       That milestone has been years in the making. Created in 2019 by the General Assembly, the Prescription Drug Affordability Board was slow to launch due in part to a veto from former Gov. Larry Hogan (R) amid pandemic-induced economic uncertainty in 2020 that delayed the board's formation. The board also cited out-of-pocket costs for consumers and state and local spending on those drugs as indicators that there may be an affordability challenge.   The board will now look at options to address the potential affordability challenge, which could include setting an upper payment limit on those drugs. But it's not clear when the state will see cost savings.   That said, some members of the health care system and the pharmaceutical industry say that policies such as upper payment limits could weaken access to life-saving drugs. Others say that the board has not engaged enough viewpoints from the health care industry. https://marylandmatters.org/2025/07/29/state-board-determines-two-type-2-diabetes-drugs-may-be-unaffordable/   XX One year after it was revealed that Chrissy Teigen and John Legend's son, Miles, was diagnosed with type 1 diabetes, Teigen is revealing how she's making her son feel more included. Teigen first opened up about her 7-year-old son's diagnosis after she and her two oldest kids, Miles and 9-year-old daughter Luna were at the 2024 summer Olympics cheering on Simone Biles. Teigen posted a photo of Miles and Luna holding up a sign. Also visible in the picture was the insulin pump on Miles' arm. Now, Teigen is sharing some insight into how she's making Miles more comfortable with having type 1 diabetes, including giving LeBron James' Barbie doll type 1 diabetes as well. In a video shared on Instagram, Teigen is seen taking the T1D Barbie, removing her insulin pump and gluing the pump onto LeBron James' Barbie. “Turning T1D Barbie into T1D Lebron James for my son,” Teigen captioned the video, revealing James is Miles' hero. 41 million followers https://www.yahoo.com/lifestyle/articles/chrissy-teigen-gives-lebron-james-154608782.html  

While AI excels at repetitive tasks like triaging medical information calls, document retrieval, and adverse event detection, the industry must address valid concerns from physicians (41% are excited but concerned, according to AMA studies) and patients who distrust AI systems. In this episode, IQVIA's Louise Molloy advocates for complete transparency, including clear disclaimers when AI generates or supports responses, arguing that the industry serves as "custodians, not owners" of patient data with ethical responsibilities.This episode is presented in partnership with ⁠IQVIA⁠.Host⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestLouise Molloy, Associate Director Medical Information & Pharmacovigilance, IQVIADisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA. Marie returns to the program to unpack how AI and automation technologies are transforming drug safety workflows. Together with Emerj Editorial Director Matthew DeMello, she shares how IQVIA uses natural language processing (NLP) built on safety-specific training data to surface early signals from massive, multilingual datasets. She also explains why combining NLP with automation tools, such as RPA and OCR, leads to higher accuracy in adverse event detection, especially across social media and non-traditional data channels. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Michael Kleinrock, lead research director at IQVIA, joined Over the Counter to discuss the importance of his company's Understanding the Use of Medicines in the US 2025 report.

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody discovery with AI”.  In the first article, Deepika Khedekar, Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. In the second article, DDW Editor Reece Armstrong, speaks to Kashif Sadiq, Founder of DenovAI Biotech about the importance of computational methods in this field.

This episode focuses on how AI is transforming pharmacovigilance (PV) on a global scale, particularly focusing on the evolving role of local qualified persons for pharmacovigilance in the EU.This episode is presented in partnership with IQVIA.Host⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestAna Pedro Jesuíno, Global Head Local QPPV Network, IQVIADisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

人工模拟人体器官，这种科幻小说般的情节，正通过类器官技术变为现实。从疾病发现、药物研发到精准治疗……类器官和器官芯片技术正在重塑医学研究的格局和未来：它们不仅能够预测药物反应、优化肿瘤治疗方案，甚至有望改善器官移植的供体短缺问题。本期播客特别邀请到丹望医疗类器官药物平台负责人张龙博士，带领我们一起了解类器官技术，探索医学研究的体外宇宙。-嘉宾-张龙，丹望医疗，类器官药物平台负责人徐莹，IQVIA艾昆纬管理咨询部企业战略负责人莉莉安，《IQ老友说》主播-精华highlight-00:46 什么是类器官？01:31 目前的类器官技术只能模拟器官中很小的一个局部，但对疾病发现和药物研发都有重要价值06:41 类器官 vs. 传统的细胞系模型&小鼠模型，有哪些差异？07:07 从患者身上采样培养肿瘤类器官，就可以提前找到合适有效的药物组合10:29 费用&时间——为什么类器官受到投资者的青睐14:03 FDA 2025年4月新政：单克隆抗体药物研发中，将逐步取消动物实验15:13 一张“身份证”大小的器官芯片，可以模拟人体多个脏器之间的循环系统17:00 中国类器官的“未来已来”，政策对市场的刺激利好作用正逐渐显现19:32 目前类器官的技术壁垒有哪些？20:44 器官移植、人造肉、人造子宫…类器官或将如何改变我们的生活？23:43 类器官的未来，需要技术研发、商业化和监管法规的协同发展*本节目仅做信息交流之目的，嘉宾观点不代表任何公司立场- 制作团队 -沈旸、王心影、束菲滢- IQ老友说 -这是一档IQVIA艾昆纬的谈话类播客节目，聚焦医疗行业，网罗多元视角，激发观点碰撞，探寻新鲜洞见，让我们一起在轻松话聊的氛围中，老友说医疗，有趣又有料！- 关于IQVIA -IQVIA艾昆纬（纽交所代码：IQV）是全球领先的专注生命科学领域的高级分析、技术解决方案和临床研究服务供应商。IQVIA利用深入分析、前沿技术、大数据资源和广泛领域的专业知识，智能连接医疗生态的各个环节。IQVIA Connected Intelligence快速敏锐地为客户提供强大的数据洞察，帮助客户加速创新医疗的临床开发和商业化进程，以更好的医疗成果惠及患者。IQVIA拥有约88,000名员工，足迹遍布100多个国家/地区。IQVIA帮助生物科技、医疗器械、制药公司、医学研究者、政府机关、支付方以及其他医疗利益相关方，获得对疾病、人类行为和科技进步更深入的理解，共同朝着治愈各类疾病的方向迈进。- 互动方式 -关注IQVIA艾昆纬微信公众号，获取更多独家洞察！- 本节目由IQVIA出品，JustPod制作发行 -

Welcome to “Debunking Value, Access & Pricing Myths”—a podcast series from IQVIA's Value and Payer Evidence team where we separate fact from fiction on some of the most persistent misconceptions in the world of healthcare pricing and access.In this debut episode, your host Rebecca Coady, Principal at IQVIA, is joined by her colleague and EU HTA expert, Sian Tanner. Together, they take on a myth that's loomed large in the industry for decades: “A centralized EU HTA will never happen.”Sian, who leads IQVIA's EU HTA Solutions offering, unpacks what the reality of EU HTA implementation means for pharmaceutical teams across Europe. From challenges and timelines to strategic priorities and long-term implications for market access, they cover what you need to know—and what your team should be doing now to prepare.

Today we're talking to Hitesh Seth, Chief Architect for Financial Services & Insurance at Salesforce, and what struck me most is how he radiates genuine enthusiasm for what he does. After 25+ years in tech, he has so much fire and passion - and in this conversation, he shares how he keeps it going.Hitesh's story offers a completely different way to think about career growth and finding work that energizes rather than depletes you.You'll hear about:The mindset shift that changed everything: How he discovered that teaching others was actually the most selfish thing he could do Why he never feels bored at work: His approach to creating excitement and challenge within any roleThe power of following your curiosity: How staying genuinely interested in learning has been his career compassHow to know when it's time to move on: His rule about leaving when you want to accelerate your learning in new areasWhy passion beats planning: How his most meaningful career moves came from following what energized him, not following a prescribed pathThe "bug" you need to cultivate: That relentless drive to solve problems that keeps you up at night (in the best way)Building expertise while staying fresh: How to become deeply skilled without getting stuck in one narrow areaThe thread that weaves throughout this conversationHitesh's infectious passion for learning and problem-solving. You'll hear someone who has figured out how to stay genuinely excited about work by constantly growing, teaching others, and focusing on solving real problems that matter.About HiteshHitesh Seth is Chief Architect for Financial Services & Insurance at Salesforce, where he works with key customers globally on Data & AI/GenAI solutions. Hitesh also works closely with Salesforce Ventures teams for investing, acquisition and integration of startups/Fintechs. His career spans leadership roles at JPMorgan Chase, American Express, and IQVIA.He graduated from IIT Kanpur, is a patent holder, published author, and passionate mentor. From his early days discovering a computer in a small shop in India to leading cutting-edge technology architecture today, Hitesh exemplifies how curiosity and passion can lead to a fulfilling and thriving career.What this means for youIf you're feeling stuck, Hitesh's story shows that it's possible to build a career where you wake up excited about the challenges ahead. The key isn't finding the perfect job - it's cultivating the right mindset about learning, growth, and contribution.What resonated most with you from this conversation?Did his perspective on teaching as learning spark something for you? What resonated most with you? I'd love to hear - DM me on IG www.instagram.com/careerintechnicolor If you enjoyed this conversation, I invite you to follow the podcast and share it with someone who might need to hear this perspective! This helps more people discover these stories.Xo, BaibaSupport the show

In this episode of Denatured, Archana Hegde from IQVIA discusses the practical challenges faced by pharmacovigilance (PV) professionals as they navigate the FDA's first draft guidance for AI in drug development, published in January 2025. Hegde explains that the vagueness of the current framework is like “a recipe with no pictures and mystery ingredients." During the discussion, she highlights areas of existing confusion.This episode is presented in partnership with IQVIA.Host⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestArchana Hegde, Senior Director, PV Systems & Innovations, IQVIADisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

As AI threats are becoming more sophisticated and privacy laws and AI regulations are rapidly evolving, the need for transparency and responsible practices has never been greater.  Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

This episode of the Astonishing Healthcare podcast features Michael Kleinrock, Director, Research Development at the IQVIA Institute for Human Data Science. We explore key highlights from their most recent annual report - Understanding the Use of Medicines in the U.S. 2025 - with an eye toward implications for plan sponsors and the health benefits market. What are the key drivers of higher drug spend beyond GLP-1s? At what cost do consumers abandon prescriptions at the counter? How is biosimilar adoption going, and what impact is it having on trend? We answer these questions and many more, including how the IRA could impact innovation, vaccination rates, and what was most surprising to Michael in the data: hint, it's how much prices really changed year-over-year! Additional Reference Materials (IQVIA Institute Reports & Publications)Assessing the Biosimilar Void in the U.S.Proliferation of Innovation Over TimeRelated ContentAH048 - High-Cost Orphan Drugs, Securing Claims Data, and More, with Dr. Eric BrickerAH055 - Pharmacy Benefits 101: Stop-Loss Insurance, with Mike Miele, FSA, MAAAReplay - Innovative partnerships for GLP-1 management, with Vida HealthHow to Manage Pharmacy Benefit Spend in a GLP-1 WorldFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

Whether it's building trust or ecosystems, the key to effective consumer engagement is being open. This point was driven home repeatedly during this podcast from on the ground at Cannes.Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register!    AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket!    Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeanne Taylor Hecht, Chief Executive Officer and Chairwoman at Lexitas. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering: How Jeanne's various roles have equipped her to become a more rounded CEO and board member. How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice. Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat. Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS? Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients.  Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler's Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University's master's in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university's Ross School of Business. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

This episode focuses on how IQVIA is innovating with agentic AI to drive efficiency and quality in clinical trials.  In this episode you will:   Discover how agentic AI can be leveraged to enhance efficiency and quality in clinical trials and help increase the chance of success. See how an agentic AI approach can optimize site selection, trial design, and other critical elements in clinical trials. Learn about using agentic AI to identify new indications and targets in early clinical development by analyzing data from multiple databases. Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA's Research and Development Solutions.

In a dynamic regulatory environment, IQVIA's Michelle Gyzen suggests that AI may be the best and only way to keep with changes that are happening daily–and sometimes hourly.In this discussion Lori and Michelle touch on the governance frameworks for cybersecurity, risk, and how AI transformation and integration is evolving to help regulatory professionals navigate the speed and complexity of global requirements.Host⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestMichelle Gyzen, Sr. Director, Strategic Regulatory Solutions; Head of Regulatory Services Innovation & Technology, IQVIA

This week, Nicolle and Taylor from Finch Marketing are joined by Jeff Ward, our trusted partner at IQVIA, to break down how we harness the power of IQVIA's data to create laser-focused campaigns that convert for our clients. We explore the strategies behind smart targeting—and why precision beats broad strokes in today's digital landscape. Whether you're a startup or seasoned business, you'll walk away with tools to dial in your message and build deeper connections with your target audience. Tune in and get data-savvy!

Lori Ellis, head of insights and Ian Fisher, head of development of analytics at IQVIA, discusses the critical importance of Target Product Profiles (TPPs) for life sciences companies, especially during uncertain times with funding challenges. Fisher emphasizes that TPPs serve as strategic guiding light which help companies articulate their development goals and demonstrate value to potential investors and partners.This episode is presented in partnership with IQVIA.Host⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuestIan Fisher, Head of Development Analytics, IQVIA

While few doubt the opportunity represented by real-world evidence, some concerns remain about its validity compared to traditional forms of clinical evidence, particularly among regulators. To address these concerns, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, suggests that incorporating some elements of traditional trials, such as randomization, is a good way to persuade regulators that RWE can be used for consumer health innovation, for example in generating new claims or supporting Rx-to-OTC switch. Looking forward, Spitzer is excited about the ways in which digital health tools and artificial intelligence can be used to expand the scope of RWE as well as drive personalization for consumers. Timestamps: 3:00 - Addressing concerns about RWE's scientific rigour and validity 12:00 – Regulators' views of RWE, particularly for consumer health 16:00 – Use of RWE for Rx-to-OTC switch 22:00 – The future of RWE Guest Bio: Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Spitzer has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.

Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA, who joins us to explore the overlooked intersection of AI and safety workflows in life sciences. As the industry experiences an explosion in the volume and diversity of data—from social media and call centers to audio and video files—Marie outlines the mounting challenges for pharmacovigilance and the opportunities AI is unlocking for healthcare and life sciences leaders. Marie discusses how advancements in voice-to-text transcription and automation are helping safety teams manage massive datasets, pinpoint potential risks, and reallocate human resources toward high-value activities like signaling and benefit-risk management. She also shares insights into where human expertise remains essential, particularly in interpreting complex clinical contexts that AI alone cannot fully capture. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

The potential for real world evidence (RWE) is huge, according to enthusiasts, but to the uninitiated it can seem like a complicated and forbidding subject. In this Over the Counter double episode, IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer, makes understanding real world evidence easy. We start with the basics, with what it is and what companies need to know about it, and what the key difference is with randomised control trials. Many companies are already using real world evidence, Volker notes, and he extracts some key lessons for companies interested in trying it out based on his extensive experience working with industry on such projects. Timestamps 2:00 – Introductions 4:00 – What is real world evidence? 5:00 – Can RWE and clinical trials complement each other? 10:00 – Why RWE is particularly attractive today 14:00 – Don't reinvent the wheel 18:00 – Why is this important for consumer health companies? 25:00 – Why RWE is often a good value option, especially for SMEs 33:00 – Applications of RWE in consumer health Guest Bio Volker Spitzer has more than 30 years of R&D experience spanning the consumer health sector, ingredients industry, and academia. Beginning his career as a professor in pharmaceutical sciences, he ascended to global positions encompassing R&D, innovation, licensing/M&A, and medical marketing at firms like Roche, DSM Nutritional Products, and Bayer. Since October 2017, Volker has been affiliated with IQVIA Consumer Health, serving as the vice president for global R&D and RWE Services. His purview primarily includes clinical research, RWE, virtual trials, and the burgeoning field of digital health. He has penned over 80 scientific publications, whitepapers and textbooks centered on science and innovation.

Le vice-président américain JD Vance achève une visite en Inde où il y a rencontré le Premier ministre Narendra Modi, pendant laquelle les deux ont négocié au sujet des mesures tarifaires envisagées par Donald Trump. À l'ordre du jour notamment, les médicaments, car l'Inde est un géant de l'industrie pharmaceutique. C'est un euphémisme d'affirmer que les États-Unis sont extrêmement dépendants des médicaments produits en Inde : près d'un générique sur deux consommés y est fabriqué. On parle ici de traitements contre l'hypertension, les troubles de la santé mentale ou encore le diabète. Car il faut le rappeler, si l'Inde est le premier fournisseur de médicaments au monde, c'est aussi le premier fournisseur des États-Unis. L'an passé, ce sont près de 13 milliards de dollars de médicaments indiens qui ont été exportés sur le sol américain.Pourtant, avant la pause de Donald Trump et donc les négociations en cours, l'Inde était visée par les droits de douane américains, puisqu'il était question d'une surtaxe de 26%. Cela veut donc dire que tout produit fabriqué en Inde arrivant aux États-Unis pourrait être taxé à cette hauteur, y compris donc les médicaments.À lire aussiEn visite en Inde, J.D. Vance affiche son optimisme commercial et sa proximité idéologique avec Narendra ModiÉconomiquement avantageux, sanitairement dangereux Mais il ne s'agit pas de marchandises lambda : il est question de santé publique. La conséquence de l'application des mesures tarifaires de Donald Trump, c'est évidemment un risque sur la santé des Américains en raison d'une hausse des prix.Car les coûts de production en Inde sont trois à quatre fois moins élevés qu'aux États-Unis. Cela permet à Washington d'économiser des milliards de dollars en frais de santé. Rien qu'en 2022, d'après le cabinet de conseil IQVIA, les économies réalisées grâce aux génériques indiens se sont élevées à 219 milliards de dollars.Un pas vers Donald TrumpSi l'objectif de Donald Trump, c'est de relocaliser la production aux États-Unis, cela ne se fait pas du jour au lendemain. Les Américains ne disposent pas forcément des principes actifs sur leur sol pour fabriquer les médicaments en tant que tels. D'autant que leur deuxième fournisseur, c'est la Chine, pays le plus touché par les mesures du président américain. Devant telle situation, plusieurs géants européens présents en Inde notamment ont annoncé des investissements massifs aux États-Unis, avec l'ambition d'anticiper les hausses des prix. Le laboratoire Roche prévoit 50 milliards de dollars pour renforcer ses capacités de production et de diagnostic sur le sol américain. Novartis de son côté parle de 23 milliards sur cinq ans. Donc pour le moment, si on ne s'en tient qu'aux annonces, le président américain obtient des résultats. Mais pour toutes les raisons que l'on vient de détailler, Washington et New Delhi n'ont pas d'autres choix que de discuter. Le bras de fer est diplomatique, mais aussi économique. On a pu le voir ces dernières heures avec la visite de JD Vance à New Delhi. Sauf que la particularité, c'est qu'à court terme, pour les Américains, il est impossible de remplacer l'approvisionnement indien. Ces produits sont vitaux, car l'Inde est un véritable pilier de la santé aux États-Unis. C'est en fait l'un des meilleurs exemples de produit à demande inélastique, à savoir des produits dont on ne peut pas se passer. La question maintenant, c'est jusqu'à quel prix ! À lire aussiComment l'Union européenne compte éviter les pénuries de médicaments?  

This podcast features malaria experts Caroline Boulton (Global Program Head, Malaria, at Novartis); Sherwin Charles (CEO, Goodbye Malaria); and Carlos Chaccour (Researcher and Visiting Scholar, Navarra Institute for International Development). The conversation delves into the current malaria response, examining shifts in international funding, R&D innovations, drug resistance challenges, emerging prevention tools, and the impact of climate change.The podcast is hosted by IQVIA's Daniel Mora-Brito, Engagement Manager, Global Health, EMEA Thought Leadership.

In this episode, IQVIA MedTech experts Michelle Edwards and Michaela Miller discuss key trends shaping the MedTech industry in 2025. The conversation covers advancements in 3D printing, real-world evidence (RWE), and clinical AI, among others. Read Ten MedTech Trends to Watch in 2025 to learn more. https://www.iqvia.com/locations/united-states/library/insight-brief/ten-medtech-trends-to-watch-in-2025Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Michelle Edwards, Practice Lead, U.S. MedTech Real World and Clinical Solutions, IQVIA

This podcast episode features a discussion between Jeff Pilch from IQVIA and Sanjay Mistry from Molnlycke. Together, they explore the journey of how their companies collaborated to solve a significant business problem related to customer master data management (MDM). Sanjay explains the challenges Molnlycke faced in defining and managing customer data across different units, which hindered their ability to perform basic analytics and customer segmentation. Jeff and Sanjay then discussed the solutions proposed by IQVIA, emphasizing a practical, incremental approach to implementing MDM and data governance, which helped Molnlycke achieve better data management and business efficiency.Featured Speakers:Jeff Pilch - MDM Practice Lead, IQVIA Sanjay Mistry - Director Data Operations, Commercial Excellence at Molnlycke

On International HPV Awareness Day, Dr. Nicola Paul hosts Dr. Tando Gaqana, a passionate HPV vaccine advocate, and Daniel Mora-Brito, IQVIA's thought leader in global health, to discuss the impact of Human Papillomavirus (HPV) in South Africa, highlighting the importance of vaccination and regular screening to prevent HPV-related conditions in Africa.

James Hatfield is the Chief Revenue Officer at Liveswitch and with extensive leadership experience in companies like IQVIA and Sageworks. Liveswitch uses instant video to drive less, give more estimates, assess issues remotely, pre-qualify leads better, and document your work. With a simple click and no apps, LiveSwitch Contact is the fastest and easiest way to connect with customers and team members to make more money and save time. James co-founded a company that turned financial statements into plain language for small business owners, leading it to become an Inc. 500 company and eventually sold it to KKR. He emphasizes the importance of "grit" and resilience in business, especially in the face of rejection or adversity and advocates for collecting feedback and using it to improve your business, which he refers to as "delighting the customer." James recommends forming a personal board that includes people from different industries and backgrounds.   Website: LiveSwitch LinkedIn: James Hatfield   Check out our CEO Hack Buzz Newsletter–our premium newsletter with hacks and nuggets to level up your organization. Sign up HERE.  I AM CEO Handbook Volume 3 is HERE and it's FREE. Get your copy here: http://cbnation.co/iamceo3. Get the 100+ things that you can learn from 1600 business podcasts we recorded. Hear Gresh's story, learn the 16 business pillars from the podcast, find out about CBNation Architects and why you might be one and so much more. Did we mention it was FREE? Download it today!

This episode focuses on using AI for indication selection and prioritization to optimize the value of clinical development planning. In this episode you will:  Discover how AI can ensure faster, better clinical development and decision making to help get drugs to market faster. See how AI can be leveraged to prioritize hundreds of indications into high-potential opportunities rapidly. Learn about using AI to look at clinical trial data to help predict the future competitive intensity for an indication.  Speaker: Raja Shankar, Vice President of Machine Learning in IQVIA's Research and Development Solutions.

Com o tempo seco, o nariz pode facilmente ficar ressecado e perder sua capacidade de filtrar as impurezas do ar. Por isso, fazer uma lavagem de alto volume no nariz diariamente com soro fisiológico pode ajudar em uma melhor respiração, e também diminuir aquela sensação de nariz entupido.Neste episódio, dr. Drauzio convida o médico otorrinolaringologista dr. Marcel Menon e a fisioterapeuta cardiorrespiratória Genai La Torre, para explicar como incorporar essa prática na rotina e a importância de manter a região sempre limpa.Conteúdo produzido em parceria com o Nasoar, a marca pioneira em lavagem nasal de alto volume no Brasil.¹Referência 1: IQVIA. PMB: Lançamento de MarcasVeja também: Como fazer lavagem nasal em crianças?

In this episode, Dr. Vishakha Sharma, Senior Principal Data Scientist at Roche Diagnostics shares her perspectives on the potential of GenAI to improve patient outcomes, enhance the efficiency of healthcare delivery, and reduce costs. She also addresses some of the key issues surrounding data interoperability and data integration when dealing with diverse data sources and unstructured data. The discussion brings attention to the need for guiding principles and highlights the ethical frameworks.Host: Michaela Miller, Practice Lead, U.S. MedTech Technology & Analytics, IQVIAFeatured Speaker: Vishakha Sharma, Ph.D., Senior Principal Data Scientist, Roche Diagnostics

Georgie Kovacs is a seasoned professional with over two decades of healthcare expertise, having contributed to industry giants like Pfizer, Syneos Health, IQVIA, and Bristol-Myers Squibb. She launched Fempower Health in 2020, a pioneering platform that empowers women with evidence-based insights and support. Collaborating with top experts, Georgie is dedicated to redefining the narrative surrounding women's health, ensuring every woman has the knowledge and resources to thrive and make informed decisions about their health. In this episode, Georgie opens up about her personal and professional story, shaped by her roots as the daughter of Hungarian immigrants and the challenges of forging her path in the healthcare industry. Discover her unique approach to overcoming obstacles, her mental strength cultivated through long-distance running, and the lessons she's learned about breaking down big problems into manageable steps. Tune in for a conversation filled with vulnerability, grit, and actionable insights that will leave you inspired to tackle your own challenges head-on. Don't miss Georgie's powerful message about persistence, self-discovery, and creating a meaningful impact in the world. Website- https://www.fempower-health.com/ Social Media Links/Handles- https://www.instagram.com/fempowerhealth https://www.youtube.com/@fempowerhealth

Taking the first steps towards becoming a skills-based organisation is exciting—but what does it really take to get started? In this episode of the Digital HR Leaders Podcast, David Green sits down with Christophe Cabrera, Director and Head of IT Talent and Company Reputation at UCB, to share an honest look at the early days of their transformation. Unlike the polished success stories we often hear, this conversation is all about the reality of starting out: what works, what doesn't, and how to build momentum. Here's what you can expect: The biggest challenges in getting started, from outdated approaches to experimenting with AI How UCB used proof-of-concept to build confidence in AI-powered solutions Managing the complexities of a workforce spread across production, clinical and office roles Keeping their skills framework agile as new competencies emerge Defining what success looks like, with internal mobility and personalised learning leading the way This conversation, sponsored by TechWolf, is an honest and practical look at what it takes to get started with skills-based management. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Christophe Cabrera: LinkedIn MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

How can HR leaders design company cultures that are intentional, adaptive and aligned with business goals? To answer this question, in this episode of the Digital HR Leaders podcast, David Green sits down with Melissa Daimler, Chief Learning Officer at Udemy and author of ReCulturing: Design Your Company Culture to Connect with Strategy and Purpose for Lasting Success. With years of hands-on experience at Adobe, Twitter, WeWork, and now Udemy, Melissa brings a wealth of practical insights on how to build cultures that stand the test of change. Here's what you can expect from this conversation: How trends like skills-based strategies, AI and flexible working are reshaping workplace culture What a healthy culture really looks like—and how to build it intentionally How Udemy is aligning its culture with skills-focused goals and preparing for AI's growing impact Tips for staying clear and aligned as priorities shift rapidly Common missteps organisations make when trying to design culture—and how to avoid them This episode, sponsored by TechWolf, is packed with real-world advice and insights that HR and learning leaders can start applying right away. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Melissa Daimler: LinkedIn MyHRFuture Academy: MyHRFuture Insight222: Insight222 TechWolf: TechWolf Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company's platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez also discusses how this affects the potential of AI and ML. LINKS:    Bionavigen A-Alpha Bio Specifica 

What better way to learn about the makes or breaks of skills initiatives than from an organisation whose mission is to deliver reliable skills data across the workforce? Joined by Mikaël Wornoo, co-founder of TechWolf, host David Green explores how organisations can move beyond surface-level skills discussions to drive real business impact. Sharing lessons learned from working with global organisations, this episode covers: How organisations are innovatively applying skills data to solve business challenges Contrasts between US and European approaches to skills that could shape your global workforce strategy The hidden challenges that derail skills projects and what companies often miss when trying to “get started” The roles required to build a truly effective skills team Why AI isn't just the future of skills intelligence but the catalyst for shifting how organisations define and measure talent This episode, sponsored by TechWolf, isn't about skills for the sake of skills—it's about reframing workforce intelligence as a strategic lever for measurable business outcomes. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: TechWolf: TechWolf MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

On this episode host Fred Goldstein invites Elizabeth Powers, Vice President and General Manager, Regulatory Science and Study Innovation at IQVIA, to discuss Real World Evidence. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Tessa Pugh, ex-CEO & Co-Founder at PharmaReview. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tessa, covering: How Tessa's bullish attitude led to her becoming a co-founder at PharmaReview Being the 'less educated person in the office', and using that to drive the growth of the business Opting not to leave after the sale of the business, and becoming the CEO Being the star player within a PE portfolio, leading to a quick exit to IQVIA Life lessons on having your cake...and eating it! Tessa Pugh is the former CEO & Co-founder PharmaReview, a Mum and an athlete. She spent 13 years working with Pharma companies and their agencies; she Co-Founded PharmaReview in 2011. Tessa was responsible for ensuring excellent client service, business development for both new and existing clients. She is a Pharma copy review process expert and became an expert in Veeva Vault functionality. Prior to this, she established a luxury direct-to-consumer cupcake company and worked in client service at some of the world's leading advertising agencies including Saatchi & Saatchi and DRAFT. She is a very proud Mum to two incredible young women. Tessa has completed several marathons; has competed in triathlons and has won an age group national title in track cycling. She is currently following a life-long dream and training to be a ski instructor.   This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter's comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In a world where artificial intelligence and workplace technologies are revolutionising how we work, the stakes have never been higher. How can organisations harness these powerful tools while ensuring fairness, ethics and compliance in a rapidly changing landscape? In this episode of the Digital HR Leaders podcast, host David Green sits down with Keith Sonderling, former Commissioner of the United States Equal Employment Opportunity Commission (EEOC), to tackle these critical questions. With a front-row seat to the challenges and opportunities at the intersection of AI and employment law, together, David and Keith explore: The promises of AI in HR—and the hidden risks leaders need to watch for How the global regulatory landscape is shaping the use of AI in the workplace Who's accountable when AI gets it wrong—and how liability is determined What HR tech vendors and HR leaders must do now to stay ahead of evolving regulations Real-world advice for embracing innovation without compromising on ethics or compliance Whether you're an HR leader navigating the rise of AI, a tech innovator shaping the future of work, or someone passionate about building a fairer workplace, this episode, sponsored by TechWolf is a must-listen. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Keith Sonderling: Keith Sonderling TechWolf: TechWolf MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

What can we learn from an organisation that has been a skills-based pioneer for over 30 years? At EPAM Systems, building a future-ready, skills-based workforce has been a foundational strategy, positioning the company as one of the most mature examples in the field. In this episode of the Digital HR Leaders podcast, host David Green is joined by Sandra Loughlin, Chief Learning Scientist at EPAM Systems, to discuss the lessons EPAM has learned over its decades-long journey and how organisations can apply these insights to their own skills transformations. Together, they dive into: The structure and strategy behind EPAM's skills-based evolution, shaped by 30 years of experience in skills management Common myths around skills-based organisations The importance of defining the work itself before pinpointing necessary skills Practical guidance on selecting the right technology to support skills-based practices Approaches to validating skills data, moving beyond self or manager assessments to more reliable data sources Insights on tailoring a skills strategy to different industries and functions, and determining when high-quality skills data is a must This episode, sponsored by TechWolf, is essential for HR leaders seeking to drive business impact through robust skills data and build a truly future-ready workforce. TechWolf is an AI-powered solution focused on one mission: delivering reliable skills data for every role and every employee in your organisation. With TechWolf, companies like HSBC, GSK, IQVIA, Workday, and United Airlines have accelerated time-to-hire by 32%, boosted internal mobility by 42%, and saved around $1,000 per employee annually on talent management. Visit techwolf.com for more information. Links to Resources: Sandra Loughlin: Sandra Loughlin TechWolf: TechWolf MyHRFuture Academy: MyHRFuture Insight222: Insight222 Hosted on Acast. See acast.com/privacy for more information.

Join Rina Alexin as she hosts Aruna Adhikari, Head of Product Clinical Technologies at IQVIA, for a deep dive into the lessons and philosophies that shaped Aruna's successful career in product management. In this episode, Aruna shares insights from over two decades of experience, including her journey from electrical engineering to becoming a celebrated product leader in life sciences, recently named one of the “100 Most Inspiring People” by Pharma Voice. Discover Aruna's approach to leading with empathy, embracing humility, building cross-functional trust, and fostering a tenacious drive for innovation. Whether you're an emerging product manager or a seasoned executive, Aruna's story and wisdom offer valuable guidance on achieving meaningful, impactful product leadership.

In this episode of the Astonishing Healthcare podcast, Joe Murad, CEO of Vida Health, joins host Justin Venneri and Capital Rx Chief Clinical Officer Sara Izadi, PharmD, in the studio for a discussion about glucagon-like peptide-1 (of GLP-1) medications and how partnering to manage cardiometabolic health can help plan sponsors control costs and keep their populations healthy. Joe and Sara review the latest data, including the rising prevalence of obesity and diabetes, GLP-1 discontinuation rates, the robust GLP-1 pipeline, and they highlight the innovative partnership between Capital Rx and Vida. Together, they explore the importance of appropriate patient management, education, and support, nuances of GLP-1 prescribing like dose titration, the role of digital health technology in achieving effective healthcare outcomes and coordinating care with other providers, and what to watch for in 2025.Related ContentHow to Manage Pharmacy Benefit Spend in a GLP-1 WorldAH021 - Managing Pharmacy Costs in a GLP-1 World, with Bridget MulvennaGLP-1s are No Laughing MatterSourcesHow many adults with private health insurance could use GLP-1 drugs (KFF; 9/5)GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes (JAMA; 5/24)Poll: 1 in 8 Adults Say They've Taken a GLP-1 Drug, Including 4 in 10 of Those with Diabetes and 1 in 4 of Those with Heart Disease (KFF; 5/10)The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028 (IQVIA; 5/7)For more information about Capital Rx and this episode, please visit Capital Rx Insights.